Madico

Alnylam Pharmaceuticals is a pioneering biopharmaceutical company based in Cambridge, MA, focused on developing RNA interference (RNAi) therapeutics to transform the treatment landscape for diseases by silencing the genes responsible for their progression. Leveraging the body's natural processes, Alnylam aims to deliver targeted medicines that address both rare and prevalent diseases, prioritizing patient needs and their experiences. Driven by a profound commitment to scientific innovation, Alnylam's robust pipeline encompasses various therapeutic areas and reflects its dedication to improving lives through impactful medicines. The company also embraces corporate responsibility, seeking to extend its positive influence beyond medication development by being a supportive force for the communities it serves. Generated from the website